Medtronic's Spinal Cord Stimulation Therapy Shows Meaningful Pain Relief


Medtronic plc MDT announced three-month results from an on-label, prospective, multi-center study of Differential Target Multiplexed (DTM) Spinal Cord Stimulation (SCS) pain therapy.

  • The data showed meaningful pain relief using DTM SCS endurance therapy for chronic overall, back, or leg pain. 
  • At three months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale.
  • Related: Medtronic's Leadless Micra AV Pacing System Scores Approval In Japan. 
  • Patients also reported an average 4.3 cm decrease in back pain and an average 5.0 cm decrease in leg pain.
  • 69% of patients improved to a less disabled category as measured by the Oswestry Disability Index, with 63% having a minimal or moderate disability at 3-months compared to just 16% at baseline.
  • 75% of patients were very satisfied or somewhat satisfied with their therapy at 3-months.
  • Enrolled patients will have additional follow-up assessments at 6 and 12 months.
  • Price Action: MDT shares are down 1.09% at $107.60 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsHealth CareGeneralBriefspain managementPain Medication
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!